I

Irene L. M. Reijers

Dutch Cancer Society

ORCID: 0000-0002-7103-3219

Publishes on Clusterin in disease pathology, Cancer Immunotherapy and Biomarkers, S100 Proteins and Annexins. 137 papers and 2k citations.

137Publications

2kTotal Citations

Clusterin in disease pathology Cancer Immunotherapy and Biomarkers S100 Proteins and Annexins Nuclear Structure and Function Ferroptosis and cancer prognosis

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al.|Nature Medicine|2022

Cited by 348Open Access

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al.|Nature Medicine|2021

Cited by 333Open Access

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

Rebecca Simpson, Erin R. Shanahan, Marcel Batten et al.|Nature Medicine|2022

Cited by 226

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al.|The Lancet Oncology|2021

Cited by 211

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Gaik Tin Quah et al.|Annals of Oncology|2021

Cited by 183Open Access